# Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

> **NCT01502124** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 78 (actual)

## Conditions studied

- Growth Hormone Disorder
- Growth Hormone Deficiency in Children

## Interventions

- **DRUG:** somatropin
- **DRUG:** somatropin

## Key facts

- **NCT ID:** NCT01502124
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05-08
- **Primary completion:** 2003-03-05
- **Final completion:** 2003-03-05
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2017-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502124, "Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01502124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*